Related references
Note: Only part of the references are listed.Serous Tubal Intraepithelial Carcinoma Associated With Extraovarian Metastases
Stephanie Schneider et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2017)
Selecting Patients with Ovarian Cancer for Germline BRCA Mutation Testing: Findings from Guidelines and a Systematic Literature Review
Diana M. Eccles et al.
ADVANCES IN THERAPY (2016)
Germline mutations in BRCA1 and BRCA2 in epithelial ovarian cancer patients in Brazil
Simone Maistro et al.
BMC CANCER (2016)
Ovarian carcinoma diagnosis: the clinical impact of 15 years of change
Stefan Kommoss et al.
BRITISH JOURNAL OF CANCER (2016)
Cancer treatment and survivorship statistics, 2016
Kimberly D. Miller et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2016)
BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study
Philipp Harter et al.
GYNECOLOGIC ONCOLOGY (2016)
Inherited Mutations in Women With Ovarian Carcinoma
Barbara M. Norquist et al.
JAMA ONCOLOGY (2016)
Two decades beyond BRCA1/2: Homologous recombination, hereditary cancer risk and a target for ovarian cancer therapy
Christine S. Walsh
GYNECOLOGIC ONCOLOGY (2015)
Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer
Susan J. Ramus et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Gene-Panel Sequencing and the Prediction of Breast-Cancer Risk
Douglas F. Easton et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer
Panagiotis A. Konstantinopoulos et al.
CANCER DISCOVERY (2015)
Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer
Susan J. Ramus et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Germline and Somatic Mutations in Homologous Recombination Genes Predict Platinum Response and Survival in Ovarian, Fallopian Tube, and Peritoneal Carcinomas
Kathryn P. Pennington et al.
CLINICAL CANCER RESEARCH (2014)
Exome sequencing identifies FANCM as a susceptibility gene for triple-negative breast cancer
Johanna I. Kiiski et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Cancer Risks for BRCA1 and BRCA2 Mutation Carriers: Results From Prospective Analysis of EMBRACE
Nasim Mavaddat et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2013)
Bevacizumab in the Treatment of Ovarian Cancer
Florian Heitz et al.
ADVANCES IN THERAPY (2012)
The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy
L. C. Hanker et al.
ANNALS OF ONCOLOGY (2012)
BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation-Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group
Kathryn Alsop et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Impact of a structured quality management program on surgical outcome in primary advanced ovarian cancer
Philipp Harter et al.
GYNECOLOGIC ONCOLOGY (2011)
Effect of Screening on Ovarian Cancer Mortality The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial
Saundra S. Buys et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing
Tom Walsh et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene
Alfons Meindl et al.
NATURE GENETICS (2010)
The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions
A. C. Antoniou et al.
BRITISH JOURNAL OF CANCER (2008)
BRCA1 and BRCA2 mutation prevalence and clinical characteristics of a population-based series of ovarian cancer cases from Denmark
Marie Soegaard et al.
CLINICAL CANCER RESEARCH (2008)
Sequence Variant Classification and Reporting: Recommendations for Improving the Interpretation of Cancer Susceptibility Genetic Test Results
Sharon E. Plon et al.
HUMAN MUTATION (2008)
Surgery in recurrent ovarian cancer:: The Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR Trial
Philipp Harter et al.
ANNALS OF SURGICAL ONCOLOGY (2006)
One in 10 ovarian cancer patients carry germ line BRCA1 or BRCA2 mutations:: results of a prospective study in Southern Sweden
S Malander et al.
EUROPEAN JOURNAL OF CANCER (2004)
Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2
MC King et al.
SCIENCE (2003)
A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer
A du Bois et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2003)
Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history:: A combined analysis of 22 studies
A Antoniou et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2003)
Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer
HA Risch et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2001)
Share Paper
